Stille W, Gillissen J
Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S825-30. doi: 10.1093/clinids/7.supplement_4.s825.
Of 146 hospitalized patients treated with aztreonam for infections, primarily of the urinary and lower respiratory tracts, 142 had a satisfactory clinical response. An initial microbiologic cure was found in 106 (84%) of 126 patients. Relapse, reinfection, or superinfection occurred in 28 patients. Thirty-nine of 43 patients treated with a control drug (gentamicin, cefotaxime, cefamandole, or tobramycin) had a satisfactory clinical response, 25 of 34 such patients showed microbiologic cure, and 12 experienced relapse, reinfection, or superinfection. Short-term perioperative treatment with aztreonam in male patients whose urine was positive for gram-negative organisms was successful for 10 of 11 patients. Pharmacokinetic studies demonstrated that dosage adjustment of aztreonam in geriatric patients should be based on creatinine clearance. No nephrotoxicity was demonstrated in 10 healthy male volunteers. Satisfactory concentrations of aztreonam were found in sputum, vagina, cervix, perimetrium, myometrium, endometrium, parametrium, fallopian tube, fat, muscle, and kidney tissues.
在146例主要因泌尿道和下呼吸道感染而接受氨曲南治疗的住院患者中，142例获得了满意的临床疗效。126例患者中有106例（84%）最初获得微生物学治愈。28例患者出现复发、再感染或二重感染。43例接受对照药物（庆大霉素、头孢噻肟、头孢孟多或妥布霉素）治疗的患者中有39例获得了满意的临床疗效，34例此类患者中有25例实现微生物学治愈，12例出现复发、再感染或二重感染。对尿液革兰阴性菌呈阳性的男性患者进行氨曲南短期围手术期治疗，11例患者中有10例成功。药代动力学研究表明，老年患者氨曲南的剂量调整应基于肌酐清除率。10名健康男性志愿者未表现出肾毒性。在痰液、阴道、宫颈、子宫周围组织、子宫肌层、子宫内膜、子宫旁组织、输卵管、脂肪、肌肉和肾脏组织中发现了满意的氨曲南浓度。
